235 related articles for article (PubMed ID: 36875551)
61. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Morello A; Sadelain M; Adusumilli PS
Cancer Discov; 2016 Feb; 6(2):133-46. PubMed ID: 26503962
[TBL] [Abstract][Full Text] [Related]
62. Coexpression of
Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
[TBL] [Abstract][Full Text] [Related]
63. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
Hyrenius-Wittsten A; Su Y; Park M; Garcia JM; Alavi J; Perry N; Montgomery G; Liu B; Roybal KT
Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910981
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma.
Zhao L; Liu Y; Zhao F; Jin Y; Feng J; Geng R; Sun J; Kang L; Yu L; Wei Y
Mol Ther Oncolytics; 2020 Mar; 16():262-271. PubMed ID: 32181327
[TBL] [Abstract][Full Text] [Related]
65. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.
Wang Z; Li N; Feng K; Chen M; Zhang Y; Liu Y; Yang Q; Nie J; Tang N; Zhang X; Cheng C; Shen L; He J; Ye X; Cao W; Wang H; Han W
Cell Mol Immunol; 2021 Sep; 18(9):2188-2198. PubMed ID: 34381179
[TBL] [Abstract][Full Text] [Related]
66. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
[TBL] [Abstract][Full Text] [Related]
67. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
[TBL] [Abstract][Full Text] [Related]
68. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
[TBL] [Abstract][Full Text] [Related]
69.
Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
[TBL] [Abstract][Full Text] [Related]
70. Mesothelin as a biomarker for targeted therapy.
Lv J; Li P
Biomark Res; 2019; 7():18. PubMed ID: 31463062
[TBL] [Abstract][Full Text] [Related]
71. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
72. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.
Yang P; Cao X; Cai H; Feng P; Chen X; Zhu Y; Yang Y; An W; Yang Y; Jie J
Cell Immunol; 2021 Feb; 360():104262. PubMed ID: 33373818
[TBL] [Abstract][Full Text] [Related]
73. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
74. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
75. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
76. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
77. The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.
Xu X; Qiu J; Sun Y
Hum Vaccin Immunother; 2017 Jul; 13(7):1548-1555. PubMed ID: 28272967
[TBL] [Abstract][Full Text] [Related]
78. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
79. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.
Zhang E; Gu J; Xue J; Lin C; Liu C; Li M; Hao J; Setrerrahmane S; Chi X; Qi W; Hu J; Xu H
J Hematol Oncol; 2018 Mar; 11(1):44. PubMed ID: 29558951
[TBL] [Abstract][Full Text] [Related]
80. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
